ArticlePharmacoEconomics2015

Cost-effectiveness analysis of onabotulinumtoxinA (BOTOX(®)) for the management of urinary incontinence in adults with neurogenic detrusor overactivity: a UK perspective.

Rizwan Hamid et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.